These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 29086375)

  • 1. Combination of Anti-miRNAs Oligonucleotides with Low Amounts of Chemotherapeutic Agents for Pancreatic Cancer Therapy.
    Passadouro M; Faneca H
    Methods Mol Biol; 2018; 1699():135-154. PubMed ID: 29086375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer.
    Passadouro M; Pedroso de Lima MC; Faneca H
    Int J Nanomedicine; 2014; 9():3203-17. PubMed ID: 25061297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic ductal adenocarcinoma: metastatic disease.
    Muñoz Martín AJ; Adeva J; Martínez-Galán J; Reina JJ; Hidalgo M
    Clin Transl Oncol; 2017 Dec; 19(12):1423-1429. PubMed ID: 28623515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete pathological response after chemotherapy alone in a patient with pancreatic adenocarcinoma.
    Carbonell S; Espinosa J; Zarco A; de-Madaria E; de la Hoz J; Yuste A; Payá A; Lluís F
    Pancreas; 2012 May; 41(4):657-9. PubMed ID: 22504386
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.
    Garajová I; Le Large TY; Frampton AE; Rolfo C; Voortman J; Giovannetti E
    Biomed Res Int; 2014; 2014():678401. PubMed ID: 25250326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer.
    Ebrahimi S; Hosseini M; Ghasemi F; Shahidsales S; Maftouh M; Akbarzade H; Parizadeh SA; Hassanian SM; Avan A
    Curr Pharm Des; 2016; 22(42):6444-6450. PubMed ID: 27539232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
    Al Haddad AH; Adrian TE
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
    Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
    Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.
    Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R
    Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy.
    Papademetrio DL; Lompardía SL; Simunovich T; Costantino S; Mihalez CY; Cavaliere V; Álvarez É
    Target Oncol; 2016 Apr; 11(2):183-95. PubMed ID: 26373299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma.
    Insulander J; Sanjeevi S; Haghighi M; Ivanics T; Analatos A; Lundell L; Del Chiaro M; Andrén-Sandberg Å; Ansorge C
    Br J Surg; 2016 Aug; 103(9):1200-8. PubMed ID: 27250937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
    Ischenko I; Petrenko O; Hayman MJ
    Oncotarget; 2015 Jun; 6(18):15814-27. PubMed ID: 26158412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
    Ur Rehman SS; Lim K; Wang-Gillam A
    Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Advances in the Treatment of Metastatic Pancreatic Cancer.
    Schober M; Javed MA; Beyer G; Le N; Vinci A; Sund M; Neesse A; Krug S
    Digestion; 2015; 92(3):175-84. PubMed ID: 26372949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of active targeting, enzyme-triggered release and fluorescent dye into gold nanoclusters for endomicroscopy-guided photothermal/photodynamic therapy to pancreatic ductal adenocarcinoma.
    Li H; Wang P; Deng Y; Zeng M; Tang Y; Zhu WH; Cheng Y
    Biomaterials; 2017 Sep; 139():30-38. PubMed ID: 28582716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.
    Sonbol MB; Firwana B; Wang Z; Almader-Douglas D; Borad MJ; Makhoul I; Ramanathan RK; Ahn DH; Bekaii-Saab T
    Cancer; 2017 Dec; 123(23):4680-4686. PubMed ID: 28817187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor effects of a 'human & mouse cross-reactive' anti-ADAM17 antibody in a pancreatic cancer model in vivo.
    Ye J; Yuen SM; Murphy G; Xie R; Kwok HF
    Eur J Pharm Sci; 2017 Dec; 110():62-69. PubMed ID: 28554668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.